• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.

作者信息

Zhang Tian, George Daniel J

机构信息

Division of Medical Oncology, Department of Medicine, Durham, NC, USA.

Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, USA.

出版信息

Nat Med. 2021 Apr;27(4):586-588. doi: 10.1038/s41591-021-01320-x.

DOI:10.1038/s41591-021-01320-x
PMID:33820997
Abstract
摘要

相似文献

1
Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.免疫疗法与靶向疗法联合开启了肾癌治疗的新时代。
Nat Med. 2021 Apr;27(4):586-588. doi: 10.1038/s41591-021-01320-x.
2
A Step Ahead in Metastatic Renal Cell Carcinoma.转移性肾细胞癌的新进展
N Engl J Med. 2021 Apr 8;384(14):1360-1361. doi: 10.1056/NEJMe2101777. Epub 2021 Feb 13.
3
Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.在转移性肾细胞癌中，乐伐替尼/依维莫司联合用药比单独使用依维莫司更能提高生存率。
Clin Adv Hematol Oncol. 2015 Aug;13(8):512-3.
4
[New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma].[新药获批：乐伐替尼联合帕博利珠单抗用于晚期肾细胞癌]
Bull Cancer. 2022 Jul-Aug;109(7-8):737-738. doi: 10.1016/j.bulcan.2022.03.008. Epub 2022 May 20.
5
The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.乐伐替尼与依维莫司治疗嫌色细胞型非透明细胞肾细胞癌的疗效：一例报告及文献综述
Clin Genitourin Cancer. 2017 Oct;15(5):e903-e906. doi: 10.1016/j.clgc.2017.05.017. Epub 2017 May 25.
6
Novel Combination Shows Strong Antitumor Activity in Metastatic Renal Cell Carcinoma.新型联合疗法在转移性肾细胞癌中显示出强大的抗肿瘤活性。
Oncology (Williston Park). 2019 Dec 12;33(12):688722.
7
[Medical treatment of renal cell carcinoma].[肾细胞癌的医学治疗]
Prog Urol. 2013 Nov;23(15):1225-37. doi: 10.1016/j.purol.2013.09.011. Epub 2013 Oct 21.
8
Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma.乐伐替尼联合帕博利珠单抗治疗肾细胞癌
N Engl J Med. 2021 Jul 15;385(3):287. doi: 10.1056/NEJMc2107518.
9
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.转移性肾细胞癌的二线全身治疗：综述
Urol Oncol. 2017 Nov;35(11):640-646. doi: 10.1016/j.urolonc.2017.08.010. Epub 2017 Sep 5.
10
Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply.乐伐替尼联合帕博利珠单抗治疗肾细胞癌。回复。
N Engl J Med. 2021 Jul 15;385(3):287. doi: 10.1056/NEJMc2107518.

引用本文的文献

1
Transcriptome-based network analysis related to regulatory T cells infiltration identified RCN1 as a potential biomarker for prognosis in clear cell renal cell carcinoma.基于转录组的与调节性T细胞浸润相关的网络分析确定RCN1为透明细胞肾细胞癌预后的潜在生物标志物。
BioData Min. 2024 Nov 14;17(1):51. doi: 10.1186/s13040-024-00404-x.
2
Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions.透明细胞肾细胞癌的免疫治疗创新：当前策略与未来方向
Cancer Diagn Progn. 2024 Sep 1;4(5):558-562. doi: 10.21873/cdp.10363. eCollection 2024 Sep-Oct.
3
Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma.
靶向 STING 诱导 GSDMD 依赖性细胞焦亡并增强肾细胞癌的抗肿瘤免疫。
Oncogene. 2024 May;43(20):1534-1548. doi: 10.1038/s41388-024-03013-4. Epub 2024 Mar 28.
4
Soy isoflavone genistein attenuates the efficacy of immune checkpoint therapy in C57BL/6 mice inoculated with B16F1 melanoma and a high PD-L1 expression level reflects tumor resistance.大豆异黄酮染料木黄酮会削弱接种B16F1黑色素瘤的C57BL/6小鼠的免疫检查点治疗效果，且高PD-L1表达水平反映肿瘤抗性。
J Clin Biochem Nutr. 2024 Jan;74(1):57-62. doi: 10.3164/jcbn.23-76. Epub 2023 Oct 6.
5
Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment.高压氧通过调节肿瘤微环境促进免疫治疗的进展。
Front Oncol. 2023 Sep 15;13:1200619. doi: 10.3389/fonc.2023.1200619. eCollection 2023.
6
Preoperative low-density lipoprotein cholesterol as a predictor of favorable prognosis in patients with clear cell renal cell carcinoma.术前低密度脂蛋白胆固醇作为透明细胞肾细胞癌患者预后良好的预测指标。
Transl Cancer Res. 2023 Jun 30;12(6):1380-1391. doi: 10.21037/tcr-22-2705. Epub 2023 Jun 13.
7
Comprehensive analysis of prognostic value, immune implication and biological function of CPNE1 in clear cell renal cell carcinoma.CPNE1在透明细胞肾细胞癌中的预后价值、免疫意义及生物学功能的综合分析
Front Cell Dev Biol. 2023 Apr 3;11:1157269. doi: 10.3389/fcell.2023.1157269. eCollection 2023.
8
Multiregional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos.多区域测序分析揭示了拉丁裔胃癌肿瘤中广泛的遗传异质性。
Cancer Res Commun. 2022 Nov 28;2(11):1487-1496. doi: 10.1158/2767-9764.CRC-22-0149. eCollection 2022 Nov.
9
Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma.NR1H4 在肾透明细胞癌中的临床意义和致癌功能。
BMC Cancer. 2022 Sep 19;22(1):995. doi: 10.1186/s12885-022-10087-4.
10
Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer.鉴定APC突变作为结直肠癌免疫治疗的潜在预测指标
J Oncol. 2022 Jul 13;2022:6567998. doi: 10.1155/2022/6567998. eCollection 2022.